NASDAQ: NGENNervgen Pharma Corp Stock
$3.56-0.08 (-2.2%)
Updated May 19, 2026
NGEN Price
$3.56
Fair Value Price
$0.31
Market Cap
$283.55M
52 Week Low
$3.51
52 Week High
$5.97
P/E
-8.05x
P/B
112.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$32.20M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
5.68
Operating Cash Flow
-$14M
Beta
1.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NGEN Overview
NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NGEN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NGEN
Ranked#271 of 462
Ranked#271 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $237.45 | A | |
| $48.67 | A | |
| $1.90 | A |
Be the first to know about important NGEN news, forecast changes, insider trades & much more!
NGEN News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NGEN ($3.56) is overvalued by 1,067.2% relative to our estimate of its Fair Value price of $0.31 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NGEN ($3.56) is not significantly undervalued (1,067.2%) relative to our estimate of its Fair Value price of $0.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NGEN due diligence checks available for Premium users.
Valuation
NGEN fair value
Fair Value of NGEN stock based on Discounted Cash Flow (DCF)
Price
$3.56
Fair Value
$0.31
Overvalued by
1,067.20%
NGEN ($3.56) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NGEN ($3.56) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NGEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.05x
Industry
20.21x
Market
22.77x
NGEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
112.54x
Industry
4.72x
NGEN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NGEN's financial health
Profit margin
Revenue
$0.0
Net Income
-$19.6M
Profit Margin
0%
NGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$16.9M
Liabilities
$14.4M
Debt to equity
5.68
NGEN's short-term assets ($16.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NGEN's short-term assets ($16.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.7M
Investing
$18.4k
Financing
$12.2M
NGEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NGEN vs Biotech Stocks
Nervgen Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.